Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Sellig, Adare Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Neil Jones, Aenova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
13.08.2024 • Product
Oleochemical Production: a Complete Package Solution for Maximum Performance
Oleochemicals touch many parts of our daily lives – personal care, pharmaceuticals, food and more. Chemical compounds derived from natural oils and fats, oleochemicals can be used as raw materials or ingredients in a variety of applications. It comes as no surprise the market is projected to reach a global value of $54.4 billion by 2029.
Using Chemistry to Create Net-Zero Value Chains
In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
Formulating Innovative Concepts
Matthias Hofmann, Group Innovation & Technology Management Director at Azelis, provides an in-depth insight into the company’s innovation activities and the underlying market trends.
Innovation Through Formulation
Anna Bertona, Group CEO at Azelis, looks back on her first six month in this role and gives an insight into her plans for the company's development.
Sustainable Material Adoption in Industrial Sectors
IMCD Industrial Solutions surveyed top customers around the globe on their insights into eight key topics deemed pertinent to sustainability in industrial sectors. This article highlights some of the most important results.
24.05.2024 • Whitepaper
503A Compounding – Regulatory Basis and Industry Good Practices for Pharmacies
A recently released guidance document, ISPE Guide: 503A Compounding – Regulatory Basis and Industry Good Practices for Pharmacies, summarizes and contextualizes key information from US governmental bodies relevant to 503A pharmacies.
21.05.2024 • Whitepaper
Transition Metals in Catalysis: From Precious to Practical
Download this complimentary Article Collection today!
29.04.2024 • Whitepaper
E. Coli Bioprocessing: Pioneering Advances in Biotechnology
Download this complimentary Expert Insights eBook today!
17.04.2024 • Product
Improve Profitability And Sustainability with Activated Nickel Foam Catalysts
With foam, hydrogenation reactions are easier, more profitable and safer.
13.03.2024 • Product
Superior Calcium Complex Greases with the Lohtragon O01 Complexing Agent
Lohtragon O01 meets the demand of today´s lubrication challenges. The calcium acetate based lubricant additive provides solutions that not only enhance the performance of calcium complex greases but also align with environmental sustainability goals.
